Copper-62 ATSM as a hypoxic tissue tracer in myocardial ischemia
暂无分享,去创建一个
Harumi Itoh | Norihiro Sadato | Yoshiharu Yonekura | Katsuya Sugimoto | Tatsuro Tsuchida | Akira Nakano | Yasuhisa Fujibayashi | N. Sadato | Y. Yonekura | Y. Fujibayashi | M. Welch | T. Tsuchida | A. Waki | N. Takahashi | K. Sugimoto | H. Itoh | A. Nakano | Atsuo Waki | Norio Takahashi | Michael J. Welch | Jong-Dae Lee | Jong-dae Lee
[1] C. Dence,et al. Myocardial kinetics of fluorine-18 misonidazole: a marker of hypoxic myocardium. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] M. Graham,et al. Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] A. Nunn,et al. TcO(PnA.O-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis, characterization, and xanthine oxidase-catalyzed reduction. , 1994, Journal of medicinal chemistry.
[4] J. D. Chapman,et al. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. , 1983, Cancer research.
[5] N. Sadato,et al. Evaluation of62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer , 2000 .
[6] John M. Hoffman,et al. Binding of the hypoxia tracer [3H]misonidazole in cerebral ischemia. , 1987, Stroke.
[7] A. Sinusas,et al. Technetium-99m-nitroimidazole (BMS181321): a positive imaging agent for detecting myocardial ischemia. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] E. Braunwald,et al. Reversible ischemic left ventricular dysfunction: evidence for the "hibernating myocardium". , 1986, Journal of the American College of Cardiology.
[9] J. D. Chapman,et al. Radioiodinated 1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[10] C. H. Bayley,et al. THE PREPARATION OF SOME THIOSEMICARBAZONES AND THEIR COPPER COMPLEXES: PART III , 1960 .
[11] T G Turkington,et al. Performance characteristics of a whole-body PET scanner. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] Y. Yonekura,et al. Differential mechanism of retention of Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) (Cu-PTSM) by brain and tumor: A novel radiopharmaceutical for positron emission tomography imaging , 1995 .
[13] Y Yonekura,et al. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] Y. Yonekura,et al. Application of the new zinc-62/copper-62 generator: an effective labeling method for 62Cu-PTSM. , 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[15] T W Griffin,et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. , 1992, International journal of radiation oncology, biology, physics.
[16] Y. Yonekura,et al. Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. , 1999, Nuclear medicine and biology.
[17] Y. Yonekura,et al. Reciprocal ST-segment depression associated with exercise-induced ST-segment elevation indicates residual viability after myocardial infarction. , 1999, Journal of the American College of Cardiology.
[18] K. Krohn,et al. Characterization of iodovinylmisonidazole as a marker for myocardial hypoxia. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.